The latest selling price, how much does domestically produced lentamide cost?

Lenalidomide is a drug that has been successfully marketed in China and included in medical insurance. The domestic price is several thousand yuan. This price has been significantly reduced compared to when it was first launched, allowing more patients to have access to and use this drug. The inclusion of medical insurance has greatly reduced the financial pressure on patients, making this life-saving drug more accessible to the people.

In addition to domestic channels, patients now have one more choice. Purchase generic lenalidomide through formal and legal overseas channels. These generic drugs mainly come from countries such as India, Laos and Bangladesh, such as NATCO in India, ASEAN Pharmaceuticals in Laos, and Yaopin International in Bangladesh. The ingredients of the generic drugs they produce are basically the same as those of the original drug lenalidomide. Consistently, the price is only 500 to 1,500 yuan, which is far lower than the original drugs on the domestic market. This undoubtedly provides a more economical treatment path for the majority of patients.

Lenalidomide (Revlimid), as an immunomodulatory drug, has attracted much attention from the medical community for its unique mechanism of action against multiple myeloma. Compared with thalidomide, lenalidomide shows higher efficacy and lower toxicity, becoming a new hope for patients with multiple myeloma. In the European Union and the United States, it has been widely used as maintenance therapy in newly diagnosed patients with multiple myeloma, especially after patients have received autologous stem cell transplantation (ASCT).

Through multiple keyPhase 3 clinical trials, maintenance therapy with lenalidomide after autologous stem cell transplantation has been proven to significantly extend the progression-free survival of patients. In the IFM 2005-02 and CALGB 100104 trials, patients on maintenance therapy with lenalidomide had a significantly delayed time to disease progression compared with placebo. At the same time, in the CALGB 100104 trial, maintenance therapy with lenalidomide also significantly prolonged the overall survival of patients. Although this effect was not shown in the IFM 2005-02 trial, this does not affect the important status of lenalidomide in the treatment of multiple myeloma.